174 results about "Transferase" patented technology

An engineered microorganism comprising (i) a heterologous nucleic acid encoding a first lysophosphatidic acid acyltransferase (LPAAT) and (ii) a heterologous nucleic acid encoding a glycerol-3-phosophate acyltransferase (GPAT), a diacylglycerol acyltransferase (DGAT), or a second LPAAT; or a microorganism comprises (i) a heterologous nucleic acid encoding a first lysophosphatidic acid acyltransferase (LPAAT), and (ii) a heterologous nucleic acid encoding a glycerol-3-phosophate acyltransferase (GPAT) or a second LPAAT, optionally further comprising (iii) a heterologous nucleic acid encoding a DGAT; or a microorganism comprising (i) a heterologous nucleic acid encoding a first lysophosphatidic acid acyltransferase (LPAAT), and (ii) a heterologous nucleic acid encoding a second LPAAT, optionally further comprising (iii) a heterologous nucleic acid encoding a DGAT and / or GPAT; or a microorganism comprising a specific LPAAT2, optionally further comprising a heterologous nucleic acid encoding a glycerol-3-phosophate acyltransferase (GPAT), a diacylglycerol acyltransferase (DGAT), or a second LPAAT, and use for the production of triacylglycerol.

A clinical decision support device, comprising: a parameter acquisition module, configured to acquire measured values for markers in a biomarker combination of a subject, wherein the biomarker combination at least comprises an alpha fetoprotein, an abnormal prothrombin, γ-glutamyltransferase, and an albumin; a risk assessment module, configured to input the measured values for the markers in the biomarker combination into a calculation model to obtain an output of the calculation model as a liver cancer risk prediction result of the subject; and an output module, configured to output the liver cancer risk prediction result of the subject. Also disclosed are a sample analysis system and a method for assessing a liver cancer risk of a subject, capable of better assessing a liver cancer risk of a subject.

The application discloses a mycobacterium maltose transferase Co GlgE and an encoding gene and application thereof.The maltose transferase Co The amino acid sequence of the GlgE is shown as SEQ ID NO.1.The application discloses a maltose transferase Corallococcus derived from mycobacterium sp.EGB Co GlgE, which can disperse maltoligosaccharide with a polymerization degree (DP) X into products with a DP of X ± 2n (X ≥ 3). Co The GlgE has glycosylation modification effects on alpha-arbutin and beta-arbutin, the biological activity of the modified arbutin is significantly improved, and the application value of the arbutin as an additive of whitening skin care products is improved.

This invention provides a method for constructing and applying MDCK cells stably integrated with disialotyltransferase, relating to the field of biotechnology. The construction method includes: infecting MDCK cells with lentiviral particles, followed by culture and screening to obtain MDCK cells stably expressing porcine ST3GAL1 and porcine ST6GAL1 genes; the lentiviral particles carry porcine ST3GAL1 and porcine ST6GAL1 genes; the nucleic acid sequence of the porcine ST3GAL1 gene is shown in SEQ ID NO.1; the nucleic acid sequence of the porcine ST6GAL1 gene is shown in SEQ ID NO.2. This construction method is simple and convenient, and the constructed MDCK cells can stably express porcine ST3GAL1 and porcine ST6GAL1 genes, effectively improving the culture efficiency of swine influenza virus, and thus can be used in the preparation of swine influenza virus.

This invention discloses a method for the biosynthesis and application of fluorinated phenazine and its derivatives, belonging to the field of bioengineering technology. The invention aims to provide a method for synthesizing fluorinated phenazine and its derivatives. Specifically, it provides an in vitro enzyme cascade catalytic reaction method for synthesizing fluorinated phenazine and its derivatives, in which halogenated methyltransferase HMT1 and O-methyltransferase LaphzM, or halogenated methyltransferase HMT1 and N-methyltransferase PhzM, are added to a reaction buffer containing 1-hydroxyphenazine and its derivatives to obtain fluorinated phenazine and its derivatives. The enzyme concentrations of halogenated methyltransferase HMT1 and O-methyltransferase LaphzM are 2:1; the enzyme concentrations of halogenated methyltransferase HMT1 and N-methyltransferase PhzM are 2:1. This establishes a pathway for the synthesis of fluorinated phenazine from 1-hydroxyphenazine and its derivatives, providing a new approach for the biosynthesis of fluorinated phenazine.

Provided herein are compounds of formula (A): or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, Ry, and Rz are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (A), or a pharmaceutically acceptable salt thereof, as well as methods of using a compound of formula (A), or a pharmaceutically acceptable salt thereof, to treat various diseases and conditions mediated by nicotinamide phosphoribosyltransferase (NAMPT).

The application discloses application of platycodin D2 in preparation of a medicine for treating or relieving fatty liver, and belongs to the field of biomedical technology. The application aims to provide a medicine for treating or relieving fatty liver. The application provides application of platycodin D2 in preparation of a medicine for treating or relieving fatty liver. The platycodin D2 can down-regulate FASN protein by inhibiting palmitoyl transferase ZDHHC23, so that the effect of treating non-alcoholic fatty liver is achieved.

The invention belongs to the technical field of biological medicine, and discloses a portal cholangiocarcinoma postoperative risk prediction model based on a gamma-glutamyltransferase (GGT) dynamic change track and a construction method thereof. The method comprises the following steps: (1) collecting clinical characteristic data and survival characteristic data (including survival time and survival state) of a patient suffering from porta hepatis cholangiocarcinoma subjected to radical resection; 2) on the basis of GGT detection results at different time points in a perioperative period, dividing patients into different GGT dynamic change track types by using a latent category hybrid model; and 3) taking the clinical characteristic data and the GGT dynamic change track type as independent variables, taking survival data as response variables, screening prediction factors through LASSO regression, and constructing a multi-factor Cox regression model, namely a postoperative risk prediction model. According to the method, the dynamic evolution rule of the GGT is introduced, so that the limitation of single-time static detection is made up, the quantitative evaluation of the survival risk is realized, and a scientific basis is provided for individualized treatment and follow-up visit management.

The application discloses an acyltransferase for synthesizing polyester intermediates and application thereof. The acyltransferase is specifically a wild-type enzyme or a mutant acyltransferase variant with catalytic acyltransferase activity, which is obtained by substituting at least one of amino acid residues at positions 209, 166 and 119 in the amino acid sequence of the wild-type enzyme. The acyltransferase variant is specifically a protein with improved acyltransferase activity. Both the wild-type enzyme and the acyltransferase variant provided by the application have acyltransferase activity. The application has important application value.

Provided are a compound defined by chemical formula 1, a stereoisomer thereof, a tautomer thereof, and a pharmaceutically acceptable salt thereof. In chemical formula 1, R is a site which binds to a histone acetyl transferase region of EP300. The compound of the present invention can reduce the intracellular level of EP300. [Chemical formula 1]

The disclosure discloses a cyclodextrin glycosyltransferase with enhanced solvent tolerance and preparation thereof, belonging to the technical fields of enzyme engineering and genetic engineering. The disclosure constructs four cyclodextrin glycosyltransferase mutants with enhanced organic solvent tolerance. Among them, the mutant with the optimal tolerance to DMSO and methanol is G539I / R146F / D147N, which is 1.6 times and 1.7 times higher than that of WT, respectively; the mutant with the optimal tolerance to ethanol is R146F, which is 1.4 times higher than that of WT; the mutant with the optimal tolerance to acetone is G539I / R146F, which is 1.5 times higher than that of WT. The disclosure helps to expand the application of glycosyltransferases in organic reaction systems, improves the enzymatic efficiency of CGTase on natural hydrophobic substrates, and has great application prospects.

This invention discloses a mogroside glycosyltransferase mutant and its application in the production of sympathomimetic I, belonging to the fields of genetic engineering and enzyme engineering. The amino acid sequence of the mogroside glycosyltransferase mutant is shown in SEQ ID NO:2. Compared with the glycosyltransferase SgUGT94-289-3, the mogroside glycosyltransferase mutant of this invention (M92T / H96M / V148W protein) can significantly increase the production of sympathomimetic I. Specifically, it can increase the yield of sympathomimetic I to 81% and the specificity to 100% in enzyme engineering and biosynthesis, meeting the requirements for industrial production and possessing significant application value.

This invention discloses a nicotinamide phosphoribosyltransferase mutant, a recombinant strain, and a method for constructing the same. The mutants are I457V, G344A, Q378A, T283G, or F182A, obtained by single-point mutation of the wild-type nicotinamide phosphoribosyltransferase shown in SEQ ID NO:1. This invention utilizes a method derived from... Schizotequatrovirus By rationally designing and site-directed mutagenesis of KVP40 nicotinamide phosphoribosyltransferase, combined with metabolic engineering to block the NMN degradation pathway and enhance substrate synthesis and product transport, the yield of β-NMN by the recombinant strain during shake-flask fermentation reached 4.82 g / L. Through optimization of fed-batch fermentation conditions, the highest yield of β-NMN during fed-batch fermentation in shake flasks reached 15.60 g / L.

The object of this invention is to provide Labyrinthula microorganisms that have high sterol ester production capacity. [Solution] A Labyrinthull microorganism modified to have reduced or lost activity of sterol 24-C-methyltransferase (SMT1) compared to an unmodified strain, wherein the Labyrinthull microorganism is modified to express a modified diacylglycerol acyltransferase 2C (modified DGAT2C) gene, and the modified diacylglycerol acyltransferase 2C (modified DGAT2C) is modified to have a defect in presumed transmembrane regions 1 to 8 of the presumed transmembrane regions 1 to 12 in diacylglycerol acyltransferase 2C (DGAT2C).

This invention discloses a lipophilic yeast strain for synthesizing astaxanthin (Yersinia lipophila). Yarrowia lipolytica This invention relates to an engineered strain, its construction method, and its application. The engineered strain is a *Yersinia lipolytica* strain carrying CrtZ and CrtW. The invention utilizes genetic engineering methods to introduce a *Yersinia lipolytica* strain derived from *Rhodochophora* into a β-carotene-producing strain via genetic engineering. Haematococcus Pluvialis The β-carotene hydroxylase encoding gene (HpCrtZ) originates from the genus Paracoccus ( Paracoccus sp. The gene encoding β-carotene ketolase (PsCrtW) and the gene derived from Saccharomyces cerevisiae (Saccharomyces cerevisiae) Saccharomyces cerevisiae The method involves obtaining a genetically engineered *Yersinia lipolytica* strain that produces astaxanthin by constructing a fusion enzyme complex and fusing it with peroxisomes, endoplasmic reticulum, and lipid droplet-targeting signal peptides to obtain a *Yersinia lipolytica* strain with higher astaxanthin yield. The astaxanthin-producing genetically engineered strain constructed in this invention achieved an astaxanthin yield of 1.43 g / L in a 5 L bioreactor after pH control and continuous feeding optimization.

The application discloses a kind of high-yield O-succinyl-L-homoserine recombinant escherichia coli and its construction method and application, belong to genetic engineering and fermentation engineering technical field.The recombinant escherichia coli is expressed by expressing anti-feedback inhibition homoserine O-succinyltransferase metA fbr , aspartate ammonia-lyase aspA, aspartate transaminase aspC, 2 ketoglutarate decarboxylase sucA, dihydrothioctic acid succinyltransferase sucB and efflux protein yjeH, knock out metJ, improve intracellular NADPH availability, to enhance OSH synthesis pathway metabolic flow, precursor succinyl coenzyme A supply and product efflux.Using 5 L bioreactor for fed-batch fermentation, after fermentation 60 h, OSH production is as high as 137.4 g / L, and sugar acid conversion rate reaches 50.5%.The application provides engineering strain and technical realization path for the efficient fermentation of OSH.

This invention belongs to the field of synthetic biology and microbial engineering, and discloses a chemical-biological method for preparing the isopentenyl bibenzyl compound 2-isopentenyl-3,3',4',5-tetrahydroxybibenzyl (NPB-1575) which has anti-ischemic stroke activity. The specific disclosed method includes: (1) chemically synthesizing the substrate dihydropiperidine; (2) constructing an engineered Escherichia coli strain based on the isopentenyl utilization pathway, co-expressing hydroxyethylthiazol kinase, isopentenyl phosphokinase, isopentenyl pyrophosphate isomerase and specific isopentenyl transferase, and efficiently synthesizing the isopentenyl donor; (3) using this strain to catalyze dihydropiperidine in whole cells, the yield in a 200L fermenter can reach 2.54g / L, which is nearly 40 times higher than the existing method; (4) obtaining NPB-1575 with a purity >98.5% by macroporous adsorption resin and normal / reversed phase chromatography and recrystallization. This method uses readily available raw materials, involves simple steps, is environmentally friendly, and yields high purity, laying the foundation for the development of NPB-1575 as a new drug for ischemic stroke and showing significant application potential.

This invention discloses a method for reducing the viscosity of potato starch, belonging to the fields of enzyme engineering and biomodified starch technology. This invention provides a method for preparing macrocyclodextrin by reacting starch with 4-α-glycosyltransferase, which is then added to potato starch to provide a suitable substrate for subsequent starch processing. This application in starch processing offers a new approach and has great potential and application prospects.

The present application relates to a kind of targeting bacterial UDP-N-acetylglucosamine enolpyruvate transaminase antibacterial compound and its application, the antibacterial compound is S-(4-chlorobenzyl) chloro isothiourea, its chemical structure is as shown in formula I: I;Or its pharmaceutically acceptable salt, stereoisomer, solvate, crystal form, isotopically labeled or prodrug.The antibacterial compound of the present application can effectively inhibit the growth of klebsiella pneumoniae, including carbapenem-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae;It also has good bacteriostatic effect on escherichia coli and pseudomonas aeruginosa;It is expected to be applied to the clinical treatment of infection caused by drug-resistant klebsiella pneumoniae and high virulence klebsiella pneumoniae and other pathogenic bacteria, and has important clinical significance and social benefits.

This invention discloses a recombinant 2-O-sulfonyltransferase mutant and its preparation method, belonging to the field of biotechnology. The recombinant enzyme sequence is formed by fusing a truncated (E28~N356) mutant of hamster-derived 2-O-sulfonyltransferase (L119V-R188E-A240I) with an N-terminal maltose-binding protein (MBP) tag. The recombinant 2-O-sulfonyltransferase mutant exhibits higher activity, 1.9 times that of the recombinant wild type, and greater stability, retaining 86.6% of its activity after 5 days at room temperature. Furthermore, the soluble expression level of this recombinant mutant 2-O-sulfonyltransferase is increased by 5 times. This mutant, as a novel biocatalyst with high efficiency, stability, and controllable production costs, has significant application value and broad industrialization prospects in the industrial enzymatic synthesis of glycosaminoglycans such as heparin and heparan sulfate.

The application discloses a brain hemorrhage prognosis improvement method based on intestinal flora regulation and relates to the technical field of intestinal microecology.The application comprises the following steps: detecting feces, starting intervention if the enterococcus abundance and neuroinflammatory metabolic markers exceed the standard, stopping the use of conventional nutrient solution, perfusing a special component containing sugar analogs, blocking the energy uptake of enterococcus, simultaneously providing a carbon source for beneficial bacteria, synchronously perfusing a microsphere suspension containing a molecular capture function, adsorbing and fixing proinflammatory metabolic waste in the intestinal tract, blocking the blood entry of the proinflammatory metabolic waste, perfusing live bacteria with different functions three times in time sequence, sequentially completing the acidification of the environment, constructing a bacterial membrane barrier and repairing the intestinal epithelium, and re-detecting after each round of intervention, selecting the maintenance period or adjusting the intensity and then recycling according to the decrease of enterococcus and markers.The application can limit the competitive advantage of enterococcus in the utilization of carbon sources after brain hemorrhage by sequentially implementing competitive inhibition of the phosphotransferase system and multi-species ecological niche occupation.

A method for producing modified cells lacking mannosyl(alpha-1,3)-glycoprotein beta-1,2-N-acetylglucosamine transferase 1 ("MGAT1") activity is provided. The MGAT1 activity-deficient CHO cell line produced by this method is also provided. A method for producing glycoproteins is further disclosed.

The invention discloses a recombinant O-acetyl-L-homoserine mercaptotransferase mutant, a recombinant genetically engineered bacterium and application of the recombinant O-acetyl-L-homoserine mercaptotransferase mutant and the recombinant genetically engineered bacterium. The mutant is obtained by performing single mutation or multiple mutation on the 33rd site, the 55th site, the 237th site and the 238th site of an amino acid sequence shown in SEQ ID NO.2. The method has the beneficial effects that the method has more efficient catalytic activity and stronger substrate tolerance, has the advantages of mild conditions, less discharge of three wastes, high selectivity and high product yield when being used for catalyzing OAH and sodium methyl mercaptide to synthesize L-methionine, and has a wide development space in the aspect of industrial production of L-methionine.

The application provides a mutant of acidophilic glycosyltransferase at the 400th position and application thereof in production of salidroside, and belongs to the technical field of bioengineering. The application solves the problem of low synthesis efficiency of salidroside under acidic conditions. The application comprises an acidophilic glycosyltransferase mutant, wherein the glycosyltransferase mutant is obtained by mutating the 400th position of the amino acid shown in SEQ ID NO. 2. The mutant is mainly used for high-yield production of salidroside under acidic conditions.

This invention provides an engineered bacterium for producing ectoine, its preparation method, and its application. The engineered bacterium is prepared using a method comprising the following steps: using *Corynebacterium glutamicum* as the starting strain, feedback inhibition by aspartate kinase LysC is relieved, the activity of the gene lysE encoding lysine efflux permease is reduced, and the ectoine synthesis gene cluster ectABC is expressed. Based on this, the activity of any one or at least two of the following—diaminobutyrate acetyltransferase EctA, pyruvate carboxylase Pyc, or aspartate kinase LysC—is enhanced, and / or the activity of any one or at least two of the following—maloquinone oxidoreductase Mqo or homoserine dehydrogenase Hom—is reduced to further increase ectoine yield.

The application provides a genetically engineered bacterium for producing lactose-N-neotetraose, a construction method and application thereof. The genetically engineered bacterium satisfies the following conditions: (1) exogenous expression of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase; (2) overexpression of galactoside permease and UDP-galactose-4-epimerase; and (3) no expression or weakened expression of setA transporter protein. The applicant of the application finds through research that exogenous introduction of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase in the genetically engineered bacterium, enhancement of the expression amount of galactoside permease and UDP-galactose-4-epimerase in the genome, and reduction of the expression amount of setA transporter protein can effectively reduce the residual amount of LNT II in the LNnT synthesis pathway and improve the fermentation yield of LNnT.

The application discloses a methionine adenosyltransferase mutant and application of the mutant in immobilized reaction, the mutant is obtained by mutating an amino acid sequence of wild-type Escherichia coli methionine adenosyltransferase, the mutant enhances the interaction force between subunits by introducing a disulfide bond at a specific position; and / or, the protein stability is enhanced by constructing a connecting peptide between adjacent subunits. The mutant provided in the application enhances the thermal stability and catalytic efficiency of the enzyme, reduces the optimum reaction pH value, reduces the generation of by-products and the precipitation of a reaction solution. The mutant enzyme can maintain high activity at a temperature of about 40 DEG C, and is particularly suitable for industrial production. In addition, the immobilized form of the mutant enzyme exhibits good stability and reusability in continuous use, significantly reduces production cost, simultaneously reduces environmental pollution, improves the yield of SAM, is more suitable for large-scale industrial production, and has more market competitiveness.